Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Advanced Breast Cancer
NCT04460820Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 1 more. Started Jul 2019; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04460820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460820.